autologous CD276 car-T cells
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2019 (NCT04691713)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CD276 antigenImmunity, passive
CD276 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05722171 | Early Phase 1 (Phase 1) | Dec 27, 2022 | Huazhong University of Science and Technology, PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
| NCT05143151 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2021 | Shenzhen University |
| NCT04864821 | Early Phase 1 (Phase 1) | May 14, 2021 | PersonGen BioTherapeutics (Suzhou) Co., Ltd., Zhengzhou University |
| NCT04691713 | N/A | Sep 1, 2019 | PersonGen BioTherapeutics (Suzhou) Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| PersonGen BioTherapeutics (Suzhou) Co., Ltd. | For profit | 3 | 3 | 2 | 2019 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
| Shenzhen University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Zhengzhou University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1